Pfizer is expected to announce its second-quarter results next month, and analysts predict a single-digit drop in the company ...

Pfizer's (NYSE:PFE) stock is up by a considerable 7.5% over the past month. However, we decided to pay attention to the company's fundamentals which don't appear to give a clear sign about the ...

Pfizer's revenue slump is temporary. New launches and Seagen integration drive 2025 growth. Read here for an investment analysis of PFE stock.

Pfizer's cost-cutting boosts earnings despite revenue miss. Discover its growth strategy, strong drug portfolio & potential 29% upside. Click here to read.

Pfizer (PFE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

When factoring in the strength of its earnings outlook, PFE looks like an impressive value stock at the moment. 7 Best Stocks for the Next 30 Days ...

To track all earnings releases for Carnival visit their earnings calendar on our site. This article was generated by Benzinga's automated content engine and reviewed by an editor.

For example, Pfizer's efforts to increase operational efficiencies are translating to solid earnings growth. The big drugmaker expects $7.2 billion in total net cost savings by the end of 2027.